In contrast, stable COPD subjects with chronic sputum production are unlikely to derive rheologic benefit from standard anti-inflammatory or anti-infective therapies and efforts to develop therapies that solubilise mucins or reduce mucin production from airway epithelia require further evaluation. The gene discussed is MUC5AC; the disease is chronic obstructive pulmonary disease.